EA201390796A1 - Применение ацилированного аналога глюкагона - Google Patents

Применение ацилированного аналога глюкагона

Info

Publication number
EA201390796A1
EA201390796A1 EA201390796A EA201390796A EA201390796A1 EA 201390796 A1 EA201390796 A1 EA 201390796A1 EA 201390796 A EA201390796 A EA 201390796A EA 201390796 A EA201390796 A EA 201390796A EA 201390796 A1 EA201390796 A1 EA 201390796A1
Authority
EA
Eurasian Patent Office
Prior art keywords
application
acylated glucagon
glucagon analog
analogue
acylated
Prior art date
Application number
EA201390796A
Other languages
English (en)
Inventor
Келд Фосгерау
Дитте Рибер
Original Assignee
Зилэнд Фарма А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45607302&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201390796(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Зилэнд Фарма А/С filed Critical Зилэнд Фарма А/С
Publication of EA201390796A1 publication Critical patent/EA201390796A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Abstract

Изобретение относится к способам лечения метаболических нарушений, включая диабет, путем применения комбинации ацилированного аналога глюкагона и аналога инсулина. Изобретение также относится к набору, включающему ацилированный аналог глюкагона и аналог инсулина.
EA201390796A 2011-01-20 2012-01-20 Применение ацилированного аналога глюкагона EA201390796A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161434698P 2011-01-20 2011-01-20
PCT/IB2012/000134 WO2012098462A1 (en) 2011-01-20 2012-01-20 Combination of acylated glucagon analogues with insulin analogues

Publications (1)

Publication Number Publication Date
EA201390796A1 true EA201390796A1 (ru) 2014-07-30

Family

ID=45607302

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201390796A EA201390796A1 (ru) 2011-01-20 2012-01-20 Применение ацилированного аналога глюкагона

Country Status (20)

Country Link
US (2) US20140011733A1 (ru)
EP (1) EP2665487A1 (ru)
JP (1) JP2014504597A (ru)
KR (1) KR20140043709A (ru)
CN (1) CN103491975B (ru)
AR (1) AR085086A1 (ru)
AU (1) AU2012208349A1 (ru)
BR (1) BR112013018269A2 (ru)
CA (1) CA2824397A1 (ru)
CL (1) CL2013002085A1 (ru)
CO (1) CO6761400A2 (ru)
EA (1) EA201390796A1 (ru)
MA (1) MA34913B1 (ru)
MX (1) MX2013008005A (ru)
PE (1) PE20140969A1 (ru)
SG (1) SG192038A1 (ru)
TN (1) TN2013000251A1 (ru)
TW (1) TW201247702A (ru)
UY (1) UY33872A (ru)
WO (1) WO2012098462A1 (ru)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA020520B1 (ru) 2008-12-15 2014-11-28 Зилэнд Фарма А/С Аналоги глюкагона
EP2370459A1 (en) 2008-12-15 2011-10-05 Zealand Pharma A/S Glucagon analogues
DK2370462T3 (da) 2008-12-15 2014-09-08 Zealand Pharma As Glucagon-analoger
CN102282166B (zh) 2008-12-15 2015-04-01 西兰制药公司 胰高血糖素类似物
SG177609A1 (en) 2009-07-13 2012-02-28 Zealand Pharma As Acylated glucagon analogues
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
MX2012014961A (es) 2010-06-24 2013-02-26 Zealand Pharma As Analogos de glucagon.
TWI596110B (zh) 2011-09-23 2017-08-21 諾佛 儂迪克股份有限公司 新穎升糖素類似物
IN2014MN02304A (ru) 2012-05-03 2015-08-07 Zealand Pharma As
AR091866A1 (es) 2012-07-23 2015-03-04 Zealand Pharma As Analogos del glucagon
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
RU2678134C2 (ru) * 2013-03-14 2019-01-23 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Конъюгаты инсулин-инкретин
WO2014170496A1 (en) 2013-04-18 2014-10-23 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use
US9988429B2 (en) * 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
UA122767C2 (uk) * 2013-10-17 2021-01-06 Зіленд Фарма А/С Ацильований аналог глюкагону
CA2929459C (en) 2013-11-06 2022-05-03 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
EA035688B1 (ru) 2013-11-06 2020-07-27 Зилэнд Фарма А/С Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip
AR098616A1 (es) 2013-12-18 2016-06-01 Lilly Co Eli Péptido para el tratamiento de hipoglicemia severa
MA46146A1 (fr) 2014-01-20 2020-12-31 Hanmi Pharm Ind Co Ltd Insuline a action prolongée et utilisation associée
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
AR100695A1 (es) 2014-05-30 2016-10-26 Hanmi Pharm Ind Co Ltd Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón
CN106536547A (zh) 2014-06-04 2017-03-22 诺和诺德股份有限公司 用于医疗用途的glp‑1/胰高血糖素受体共激动剂
US10232020B2 (en) 2014-09-24 2019-03-19 Indiana University Research And Technology Corporation Incretin-insulin conjugates
BR112017008659A2 (pt) 2014-10-29 2018-01-30 Zealand Pharma As ?métodos e compostos de agonista de gip?
AU2016247499B2 (en) 2015-04-16 2020-09-03 Zealand Pharma A/S Acylated glucagon analogue
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
BR102015031283A2 (pt) * 2015-12-14 2018-09-18 Univ Rio De Janeiro Bioconjugado de amilina humana ou de análogos de amilinanão agregantes, composição, métodos para a preparação deuma composição, para o tratamento de uma doença oucondição e para estabilizar um composto amilino-mimético, e,medicamento
WO2017160669A1 (en) * 2016-03-18 2017-09-21 Merck Sharp & Dohme Corp. Insulin-incretin conjugates
US11058775B2 (en) 2016-04-26 2021-07-13 Merck Sharp & Dohme Corp. Insulin dimer-incretin conjugates
JP7158378B2 (ja) 2016-09-23 2022-10-21 ハンミ ファーマシューティカル カンパニー リミテッド インスリン受容体との結合力が減少された、インスリンアナログ及びその用途
US11752216B2 (en) 2017-03-23 2023-09-12 Hanmi Pharm. Co., Ltd. Insulin analog complex with reduced affinity for insulin receptor and use thereof
JP2022514835A (ja) * 2018-12-21 2022-02-16 ハンミ ファーマシューティカル カンパニー リミテッド インスリン及びグルカゴンを含む薬学組成物
CA3186427A1 (en) * 2020-06-11 2021-12-16 Abvance Therapeutics Inc. Systems, devices, compositions and methods for treating diabetes
WO2023088140A1 (zh) * 2021-11-19 2023-05-25 南京明德新药研发有限公司 订合肽及其应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3837825A1 (de) 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
ATE204882T1 (de) 1993-09-17 2001-09-15 Novo Nordisk As Acyliertes insulin
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US5461031A (en) 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
BRPI9711437B8 (pt) 1996-08-30 2021-05-25 Novo Nordisk As derivados de glp-1
CZ295838B6 (cs) 1996-09-09 2005-11-16 Zealand Pharma A/S Způsob výroby peptidů
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
ATE409193T1 (de) 1999-03-17 2008-10-15 Novo Nordisk As Verfahren zur acylierung von peptiden und proteinen
AU2002346491A1 (en) 2001-12-19 2003-07-09 Eli Lilly And Company Crystalline compositions for controlling blood glucose
EP1545460A4 (en) 2001-12-20 2005-11-16 Lilly Co Eli INSULIN MOLECULE WITH TEMPORARY EFFECT
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
KR20050121748A (ko) 2003-04-29 2005-12-27 일라이 릴리 앤드 캄파니 연장된 시간 작용을 갖는 인슐린 유사체
AU2006258841B2 (en) 2005-06-13 2012-05-03 Imperial Innovations Limited Oxyntomodulin analogues and their effects on feeding behaviour
WO2007081824A2 (en) 2006-01-06 2007-07-19 Case Western Reserve University Fibrillation resistant proteins
EP2471810A1 (en) 2006-02-22 2012-07-04 Merck Sharp & Dohme Corporation Oxyntomodulin derivatives
WO2008043033A2 (en) 2006-10-04 2008-04-10 Case Western Reserve University Fibrillation-resistant insulin and insulin analogues
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
US8454971B2 (en) 2007-02-15 2013-06-04 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
WO2008152403A1 (en) 2007-06-15 2008-12-18 Zealand Pharma A/S Glucagon analogues
NZ584825A (en) 2007-11-20 2013-03-28 Ambrx Inc Modified insulin polypeptides and their uses
DK2229407T3 (en) 2008-01-09 2017-02-27 Sanofi Aventis Deutschland NEW INSULIN DERIVATIVES WITH EXTREMELY DELAYED TIME / EFFECTS PROFILE
BRPI0907119A2 (pt) 2008-01-09 2015-07-14 Sanofi Aventis Deutschland Derivados de insulina tendo um perfil de ação de tempo extremamente retardado
DE102008003566A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
US8993516B2 (en) 2008-04-14 2015-03-31 Case Western Reserve University Meal-time insulin analogues of enhanced stability
US20110195896A1 (en) 2008-04-22 2011-08-11 Case Western Reserve University Isoform-specific insulin analogues
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
US8546327B2 (en) * 2008-06-17 2013-10-01 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
JP5753779B2 (ja) * 2008-06-17 2015-07-22 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 生理学的ｐＨの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体
PL219335B1 (pl) 2008-07-04 2015-04-30 Inst Biotechnologii I Antybiotyków Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna
JP5780958B2 (ja) 2008-07-31 2015-09-16 ケイス、ウエスタン、リザーブ、ユニバーシティ ハロゲン安定化インスリン
EA020520B1 (ru) * 2008-12-15 2014-11-28 Зилэнд Фарма А/С Аналоги глюкагона
DK2370462T3 (da) * 2008-12-15 2014-09-08 Zealand Pharma As Glucagon-analoger
EP2370459A1 (en) * 2008-12-15 2011-10-05 Zealand Pharma A/S Glucagon analogues
CN102282166B (zh) * 2008-12-15 2015-04-01 西兰制药公司 胰高血糖素类似物
US8697632B2 (en) 2008-12-19 2014-04-15 Indiana University Research And Technology Corporation Amide based insulin prodrugs
CA2747490C (en) 2008-12-19 2017-02-14 Indiana University Research And Technology Corporation Insulin analogs
CN101519446A (zh) 2009-03-31 2009-09-02 上海一就生物医药有限公司 一种重组人胰岛素及其类似物的制备方法
SG177609A1 (en) * 2009-07-13 2012-02-28 Zealand Pharma As Acylated glucagon analogues
MX343360B (es) * 2010-04-27 2016-11-03 Zealand Pharma As Conjugados peptidicos de agonistas del receptor de glp-1 y gastrina y su uso.
UY33462A (es) * 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon

Also Published As

Publication number Publication date
AR085086A1 (es) 2013-09-11
NZ612719A (en) 2015-05-29
CL2013002085A1 (es) 2013-12-06
CA2824397A1 (en) 2012-07-26
KR20140043709A (ko) 2014-04-10
CO6761400A2 (es) 2013-09-30
BR112013018269A2 (pt) 2017-06-06
JP2014504597A (ja) 2014-02-24
EP2665487A1 (en) 2013-11-27
UY33872A (es) 2012-08-31
SG192038A1 (en) 2013-08-30
TW201247702A (en) 2012-12-01
MX2013008005A (es) 2013-08-21
WO2012098462A1 (en) 2012-07-26
CN103491975A (zh) 2014-01-01
TN2013000251A1 (en) 2014-11-10
PE20140969A1 (es) 2014-07-24
MA34913B1 (fr) 2014-02-01
AU2012208349A1 (en) 2013-07-18
US20140011733A1 (en) 2014-01-09
CN103491975B (zh) 2016-05-11
US20160000883A1 (en) 2016-01-07

Similar Documents

Publication Publication Date Title
EA201390796A1 (ru) Применение ацилированного аналога глюкагона
DK3301177T3 (da) Rnai-midler, sammensætninger og fremgangsmåder til anvendelse deraf til behandling af transthyretin (ttr)-forbundne sygdomme
PH12016500675A1 (en) Acylated glucagon analogues
EA202190619A1 (ru) Противовирусные соединения
BR112014032990A2 (pt) seringa
PH12015500531A1 (en) Glucagon analogues
EA201590715A1 (ru) Производные эксендина-4 как двойные агонисты glp1/глюкагона
NZ707139A (en) Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
EA201391033A1 (ru) Ингибиторы bace-2 для лечения метаболических расстройств
EA201590058A1 (ru) Аналоги глюкагона
BR112014005234A2 (pt) tratamento de doenças relacionadas com subunididades alfa dos canais de sódio dependentes de voltagem (scnxa) com pequenas moléculas
EA201892050A1 (ru) Способ получения замещенных 5-фтор-1h-пиразолопиридинов
EA201391489A1 (ru) Композиции со сниженной вязкостью
CL2012003681A1 (es) Compuestos derivados de piperidina; composicion farmaceutica; y su uso como inhibidores de acetil-coa carboxilasa para el tratamiento de trastornos metabolicos, tales como obesidad y diabetes.
EA201200046A1 (ru) Новые соединения, фармацевтическая композиция и связанные с ними способы
MX2013011124A (es) Compuestos para el tratamiento del sindrome metabolico.
MX366636B (es) Nuevo derivado de un análogo de insulina.
DK2550985T3 (da) Plungerstempelkit til medicinsprøjte
SG178596A1 (en) Methods of treatment using anti-oxidized ldl antibodies
EA201491300A1 (ru) Композиция для назального применения с улучшенной стабильностью
MX2014003883A (es) Inhibidores de monoacilglicerol lipasa para el tratamiento de enfermedades metabolicas y transtornos relacionados.
EA201491522A1 (ru) Способы лечения нарушения походки и/или равновесия у пациентов с рассеянным склерозом с использованием аминопиридина
BR112014011898A2 (pt) métodos e composições para o tratamento de diabetes e sintomas relacionados
MX359171B (es) Tratamiento para diabetes tipo i y tipo ii.
UY33973A (es) Métodos de tratamiento dirigido de degeneración lobular frontotemporal.